Janssen Looks To Bar Sales Of Biosimilar In Remicade Suit
Celltrion Healthcare should reimburse Janssen Biotech for all lost profits stemming from alleged infringement of a patent related to Janssen's arthritis treatment Remicade, the company told a Massachusetts federal court Wednesday,...To view the full article, register now.
Already a subscriber? Click here to view full article